Page 67 - Binder2

of response” becomes a normal line item in a chart, not a
flashing warning sign. Where failure is built into the
treatment plan, not treated as a signal for innovation.

And so, the patient continues to move through the
algorithm, biologic by biologic, hoping that the next one
will work—and that this time, the immune system might
stay silent.

But silence isn’t the goal. Harmony is.
And until the system demands more than temporary
control, tolerization will continue to hide in plain sight—
encoded in our clinical routines, normalized by our
protocols, and quietly costing lives.

Consumer Cost

For patients, the journey through biologic treatment is
rarely linear. It’s fragmented—across prescribers, insurers,
infusion centers, and marketing campaigns. At each
touchpoint, they encounter a different story.

This lack of transparency isn’t just clinical. It’s emotional.
Patients are expected to trust the science, comply with the
schedule, and absorb the side effects. But when the biologic
stops working, they’re left to make sense of it alone. The
term “tolerization” doesn’t appear in their visit summary.

It’s not coded on their insurance form. It’s not in the
pamphlet they were handed at the infusion center. It's not in
the TV ad filled with smiles and sunshine

This is the human cost of a system that doesn’t track
tolerization.
Not just financial waste, but narrative erosion.

65